Open-Label Creatine Study for Female Meth Users

Depression Clinical Trial

Official title: Open-Label Creatine Monohydrate Supplementation in Depressed Female Methamphetamine Users

Status Terminated

Clinical Trial Summary

Study Purposes and Objectives:

The objectives should be stated in such a way that the reader can determine the appropriateness of the study design. If appropriate, state the specific hypotheses being tested and/or study aims. Use lay language.

Methamphetamine use is of great concern in the state of Utah because it's the primary drug of threat in the state, and is the primary drug of choice among females between the ages of 18 and 24. The primary hypothesis of the study is that eight weeks of oral creatine supplementation will result in improvements in depression rating scores in female MA users. Secondary hypotheses include the following: 1) creatine supplementation will result in a decrease in the number of positive MA screens; 2) NAA and Cr concentrations will increase after eight weeks of oral creatine supplementation; and 3) PCr/β-NTP levels in the frontal lobe using 31P MRS will increase after eight weeks of creatine monohydrate oral supplementation.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Dual Diagnosis
• Substance Use

• NCT number: NCT02189915
• Study type: Interventional
• Source: University of Utah
• Status: Terminated
• Phase: N/A
• Start date: January 2012
• Completion date: December 2016